Top

Published in:

01-02-2013 | Original Article

Nuclear factor κB activity correlates with the progression and prognosis of pancreatic cancer in a mouse model

Authors: Kenei Furukawa, Tadashi Uwagawa, Koichiro Haruki, Yuki Fujiwara, Tomonori Iida, Hiroaki Shiba, Takeyuki Misawa, Toya Ohashi, Katsuhiko Yanaga

Published in: Surgery Today | Issue 2/2013

Abstract

Introduction

Constitutive NF-κB activation is considered to play a key role in the aggressive behavior of pancreatic cancer. Although NF-κB in tumors may contribute to aggressive characteristic features via transcription of angiogenesis and invasion-related factors, there is no definitive evidence showing a correlation between quantitated NF-κB activity and prognosis. In this study, we quantitated NF-κB activity of various human pancreatic cancer cell lines and evaluated whether NF-κB activity was related to tumor progression and prognosis for pancreatic cancer in mice.

Materials and methods

We quantitated NF-κB activity in six pancreatic cancer cell lines (AsPC-1, BxPC-3, Capan-2, MIAPaCa-2, Panc-1 and PL45) and evaluated downstream target genes of NF-κB such as VEGF, IL-8 and MMP-9 in vitro. Next, we evaluated tumor progression and prognosis using subcutaneous tumor model in vivo between cell lines with the highest and lowest NF-κB activity.

Results

BxPC-3 had the highest and AsPC-1 had the lowest NF-κB activity in the 6 cell lines. Expression of VEGF, IL-8 and MMP-9 in BxPC-3 was significantly higher than those in AsPC-1 cells in vitro (p < 0.001) and tumor growth in BxPC-3 was faster than that in AsPC-1 group (p < 0.001) resulting in worse survival in vivo (p = 0.0339).

Conclusion

These results suggested that NF-κB activity is related to expression of its downstream target genes, tumor progression and prognosis in experimental pancreatic cancer model.

Niederhuber JE, Brennan MF, Menck HR. The National CancerDate Base report on pancreatic cancer. Cancer. 1995;76:1671–7.PubMedCrossRef

Sohn TA, Yeo CJ, Cameron JL, Koniaris L, Kaushal S, Abrams RA, et al. Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg. 2000;4:567–79.PubMedCrossRef

Burris HA, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997;15:2403–13.PubMed

Berlin JD, Catalano P, Thomas JP, Kugler JW, Haller DG, Benson AB 3rd. Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J Clin Oncol. 2002;20:3270–5.PubMedCrossRef

Chen F, Castranova V, Shi X. New insights into the role of nuclear factor-κB in cell growth regulation. Am J Pathol. 2001;159:387–97.PubMedCrossRef

Amer BA, David B. An essential role for NF-κB in preventing TNF-alpha-induced cell death. Science. 1996;274:782–4.CrossRef

Antwerp VDJ, Seamus MJ, Tal K, Douglas GR, Inder VM. Suppression of TNF-alpha-induced apoptosis by NF-κB. Science. 1996;274:787–9.PubMedCrossRef

Karin M, Lin A. NF-κB at the crossroads of life and death. Nature Immunol. 2002;3:221–7.CrossRef

Huang S, Robinson JB, DeGuzman A, Bucana CD, Fiddler IJ. Blockade of nuclear factor-κB signaling inhibits angiogenesis and tumorigenicity of human ovarian cancer cells by suppressing expression of vascular endothelial growth factor and interleukin 8. Cancer Res. 2000;60:5334–9.PubMed

10.

Matsumoto G, Namekawa J, Muta M, Nakamura T, Bando H, Tohyama K, et al. Targeting of nuclear factor κB pathways by dehydroxymethyleoxyquinomicin, a novel inhibitor of breast carcinomas: antitumor and antiangiogenic potential in vivo. Clin Cancer Res. 2005;11:1287–93.PubMed

11.

Kikuchi E, Horiguchi Y, Nakashima J, Kuroda K, Oya M, Ohigashi T, et al. Suppression of hormone-refractory prostate cancer by a novel nuclear factor κB inhibitor in nude mice. Cancer Res. 2003;63:107–10.PubMed

12.

Huang S, Pettaway CA, Uehara H, Bucana CD, Fidler IJ. Blockade of NF-κB activity in human prostate cancer cells is associated with suppression of angiogenesis, invasion, and metastasis. Oncogene. 2001;20:4188–97.PubMedCrossRef

13.

Wang W, Abbruzzese JL, Evans DB, Larry L, Cleary KR, Chiano PJ. The nuclear factor-κB RelA transcription factor is constitutively activated in human pancreatic adenocarcinoma cells. Clin Cancer Res. 1999;5:119–27.PubMed

14.

Wang W, Abbruzzese JL, Evans DB, Chiano PJ. Overexpression of urokinase-type plasminogen activator in pancreatic adenocarcinoma is regulated by constitutively activated RelA. Oncogene. 1999;18:4554–63.PubMedCrossRef

15.

Fujioka S, Sclabas GM, Schmidit C, Niu J, Frederick WA, Dong QG, et al. Inhibition of constitutive NF-κB activity by IκBαM suppresses tumorigenesis. Oncogene. 2003;22:1365–70.PubMedCrossRef

16.

Fujioka S, Sclabas GM, Schmidit C, Frederick WA, Dong QG, Abbruzzese JL, et al. Function of nuclear κB in pancreatic cancer metastasis. Clin Cancer Res. 2003;9:346–54.PubMed

17.

Uwagawa T, Li Z, Zhe C, Xia Q, Peng B, Sclabas GM, et al. Mechanisms of synthetic serine protease inhibitor (FUT-175)-mediated cell death. Cancer. 2007;109:2142–53.PubMedCrossRef

18.

Furukawa K, Iida T, Shiba H, Fujiwara Y, Uwagawa T, Shimada Y, et al. Anti-tumor effect by inhibition of NF-κB activation using nafamostat mesylate for pancreatic cancer in a mouse model. Oncol Rep. 2010;24:843–50.PubMedCrossRef

19.

Uwagawa T, Misawa T, Sakamoto T, Ito R, Gocho T, Shiba H, et al. A phase I study of full-dose gemcitabine and regional arterial infusion of nafamostat mesylate for advanced pancreatic cancer. Ann Oncol. 2009;20:239–43.PubMedCrossRef

20.

Dhillon N, Aggarwal BB, Newman RA, Wolff RA, Kunnumakkara AB, Abbruzzese JL, et al. Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin Cancer Res. 2008;14:4491–9.PubMedCrossRef

21.

Shimada Y, Fukuda T, Aoki K, Yukawa T, Iwamuro S, Ohkawa K, et al. A protocol for immunoaffinity separation of the accumulated ubiquitin-protein conjugates solubilized with sodium dodecyl sulfate. Anal Biochem. 2008;377:77–82.PubMedCrossRef

22.

Arlt A, Gehrz A, Müerköster S, Vorndamm J, Kruse ML, Fölsch UR, et al. Role of NF-kappaB and Akt/PI3K in the resistance of pancreatic carcinoma cell lines against gemcitabine-induced cell death. Oncogene. 2003;22:3243–51.PubMedCrossRef

23.

Arlt A, Vorndamm J, Breitenbroich M, Fölsch UR, Kalthoff H, Schmidt WE, et al. Inhibition of NF-kappaB sensitizes human pancreatic carcinoma cells to apoptosis induced by etoposide (VP16) or doxorubicin. Oncogene. 2001;20:859–68.PubMedCrossRef

24.

Wang CY, Mayo MW, Korneluk RG, Goeddel DV, Baldwin AS Jr. NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science. 1998;281:1680–3.PubMedCrossRef

25.

Weichert W, Boehm M, Gekeler V, Bahra M, Langrehr J, Neuhaus P, et al. High expression of RelA/p65 is associated with activation of nuclear factor-kappaB-dependent signaling in pancreatic cancer and marks a patient population with poor prognosis. Br J Cancer. 2007;97:523–30.PubMedCrossRef

26.

Le X, Shi Q, Wang B, Xiong Q, Qian C, Peng Z, et al. Molecular regulation of constitutive expression of interleukin-8 in human pancreatic adenocarcinoma. J Interferon Cytokine Res. 2000;20:935–46.PubMedCrossRef

27.

Shi Q, Abbruzzese JL, Huang S, Fidler IJ, Xiong Q, Xie K. Constitutive and inducible interleukin 8 expression by hypoxia and acidosis renders human pancreatic cancer cells more tumorigenic and metastatic. Clin Cancer Res. 1999;5:3711–21.PubMed

28.

Nakagawa Y, Aoki T, Kasuya K, Tsuchida A, Koyanagi Y. Histologic features of venous invasion, expression of vascular endothelial growth factor and matrix metalloproteinase-2 and matrix metalloproteinase-9, and the relation with liver metastasis in pancreatic cancer. Pancreas. 2002;24:169–78.CrossRef

29.

Aggarwal BB, Shishodia S, Takada Y, Banerjee S, Newman RA, Bueso-Ramos CE, et al. Curcumin suppresses the paclitaxel-induced nuclear factor-kappaB pathway in breast cancer cells and inhibits lung metastasis of human breast cancer in nude mice. Clin Cancer Res. 2005;11:7490–8.PubMedCrossRef

30.

Fujiwara Y, Furukawa K, Haruki K, Shimada Y, Iida T, Shiba H, et al. Nafamostat mesylate can prevent adhesion, invasion and peritoneal dissemination of pancreatic cancer thorough nuclear factor-kappa B inhibition. J Hepatobiliary Pancreat Sci. 2011;18:731–9.PubMedCrossRef

31.

Lim JE, Chien MW, Earle CCP. Prognostic factors following curative resection for pancreatic adenocarcinoma: a population-based, linked database analysis of 396 patients. Ann Surg. 2003;237:74–85.PubMedCrossRef

32.

Nakamori S, Yashima K, Murakami Y, Ishikawa O, Ohigashi H, Imaoka S, et al. Association of p53 gene mutations with short survival in pancreatic adenocarcinoma. Jpn J Cancer Res. 1995;86:174–81.PubMedCrossRef

33.

Yamamoto S, Tomita Y, Hoshida Y, Morooka T, Nagano H, Dono K, et al. Prognostic significance of activated Akt expression in pancreatic ductal adenocarcinoma. Clin Cancer Res. 2004;10:2846–50.PubMedCrossRef

34.

Sipos B, Möser S, Kalthoff H, Török V, Löhr M, Klöppel G. A comprehensive characterization of pancreatic ductal carcinoma cell lines: towards the establishment of an in vitro research platform. Virchows Arch. 2003;442:444–52.PubMed

Title: Nuclear factor κB activity correlates with the progression and prognosis of pancreatic cancer in a mouse model
Authors: Kenei Furukawa
Tadashi Uwagawa
Koichiro Haruki
Yuki Fujiwara
Tomonori Iida
Hiroaki Shiba
Takeyuki Misawa
Toya Ohashi
Katsuhiko Yanaga
Publication date: 01-02-2013
Publisher: Springer Japan
Published in: Surgery Today / Issue 2/2013
Print ISSN: 0941-1291
Electronic ISSN: 1436-2813
DOI: https://doi.org/10.1007/s00595-012-0279-5

ACC 2024 Congress

Springer Medicine

Nuclear factor κB activity correlates with the progression and prognosis of pancreatic cancer in a mouse model

Abstract

Introduction

Materials and methods

Results

Conclusion

ACC 2024 Congress

Springer Medicine

Abstract

Introduction

Materials and methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 2/2013

Solid-pseudopapillary neoplasms of the pancreas: clinical and pathological features of 33 cases

Associated expression of α2,3sialylated type 2 chain structures with lymph node metastasis in distal colorectal cancer

Infraareolar access for thoracoscopic sympathectomy to treat primary hyperhidrosis

Validation of online calculators to predict the non-sentinel lymph node status in sentinel lymph node-positive breast cancer patients

The possibility of using fibrin-based collagen as an antibiotic delivery system

Intraoperative fluorescence lymphography using indocyanine green in a patient with chylothorax after esophagectomy: report of a case